Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The HOPE Study. What does it contribute to general practice?].

J Mann1, P Sleight

  • 1Klinikum Schwabing, München. tbno2ab@mail.lrz-muenchen.de

MMW Fortschritte Der Medizin
|January 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-Compassion and Parenting in Mothers and Fathers with Depression.

Mindfulness·2016
Same author

Pseudomonas aeruginosa Induced Airway Epithelial Injury Drives Fibroblast Activation: A Mechanism in Chronic Lung Allograft Dysfunction.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Proliferating subcutaneous nodules in a 12-year-old girl.

Clinical and experimental dermatology·2015
Same author

Corrigendum: NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Nature communications·2015
Same author

A national survey of Mohs micrographic surgery in the U.K.

The British journal of dermatology·2015
Same author

NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Nature communications·2015
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
See all related articles

The HOPE study found that ramipril, an ACE inhibitor, significantly reduced cardiovascular events like heart attacks and strokes in high-risk patients. These benefits, including cardio- and nephroprotection, were observed even without substantial blood pressure reduction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • High cardiovascular risk necessitates effective preventative strategies.
  • The Renin-Angiotensin System (RAS) plays a crucial role in cardiovascular regulation.
  • Angiotensin-Converting Enzyme (ACE) inhibitors are a class of drugs targeting the RAS.

Purpose of the Study:

  • To investigate if inhibiting the RAS with ramipril prevents cardiovascular events in high-risk individuals.
  • To evaluate the efficacy of ramipril in reducing myocardial infarction, stroke, and cardiovascular death.

Main Methods:

  • The Heart Outcomes Prevention Evaluation (HOPE) study was a double-blind, placebo-controlled trial.
  • Participants were patients with high cardiovascular risk.
  • The primary endpoint combined myocardial infarction, stroke, and cardiovascular death.

Related Experiment Videos

Main Results:

  • Ramipril significantly reduced myocardial infarction rates (9.9% vs. 12.2%) and cardiovascular deaths (6.1% vs. 8.1%).
  • Strokes (3.4% vs. 4.9%) and revascularizations (16.0% vs. 18.6%) were also significantly decreased.
  • A notable increase in cough rate (5%) was observed with ramipril.
  • Benefits were largely independent of blood pressure reduction and particularly pronounced in type 2 diabetics.

Conclusions:

  • Ramipril effectively prevents major cardiovascular events in high-risk patients.
  • Cardio- and nephroprotective effects are significant, especially for type 2 diabetics.
  • Albuminuria is a marker for cardiovascular event risk.